Matinas BioPharma Announces Publication of Results from Phase 1 Portion of the EnACT Study Investigating Safety and Tolerability of MAT2203
Stock Information for Matinas Biopharma Holdings Inc.
Loading
Please wait while we load your information from QuoteMedia.